Evercore ISI Keeps an “In Line” Rating on Guardant Health, Inc. (GH)

Guardant Health, Inc. (NASDAQ:GH) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.

On May 8, Evercore ISI analyst Vijay Kumar raised Guardant Health, Inc. (NASDAQ:GH)’s price objective to $95 from $90. It kept an “In Line” rating on the shares.

On May 7, Guardant Health, Inc. (NASDAQ:GH) released its Q1 2026 financial report. The revenue was $301.7 million, marking a 48% YoY growth. The firm credited the rise to oncology sales of $205.0 million, up by 36%, while the biopharma and data revenue surged by 17%. The screening revenue came in at $41.6 million.

The company had a non-GAAP gross margin of 66% and improved from 65%. It had a gross profit of $196.7 million, soaring by 53%. Guardant Health also reported a net loss of $112.1 million, up from $95.2 million.

Photo by National Cancer Institute on Unsplash

Helmy Eltoukhy, co-founder and co-CEO, said the revenue increase simply shows “strong momentum.” The oncology test volume climbed by 47% to 86,000 tests. Meanwhile, co-founder and co-CEO AmirAli Talasaz noted that Shield volume momentum helps future growth.

Guardant Health, Inc. (NASDAQ:GH) also upgraded its revenue outlook for 2026 to $1.30 billion to $1.32 billion, representing growth of 32% to 34%.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology firm. It provides cancer treatment using blood tests, data sets, and analytics.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.